{
  "first_published_at": "2010-04-01", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087708", 
  "title": "Becaplermin (Regranex) for diabetic ulcers: contraindicated in patients with any known current cancer", 
  "tags": "{\"parsed_therapeutic\": [\"endocrinology-diabetology-metabolism\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Endocrinology, diabetology and metabolism\"]}", 
  "_document_number": 207, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/change_icon.png", 
  "therapeutic_area": [
    "endocrinology-diabetology-metabolism"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Becaplermin (Regranex) for diabetic ulcers: contraindicated in patients with any known current cancer</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: April 2010</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--A retrospective observational study (unpublished) has raised concerns of a link between becaplermin and malignancies distant from the site of application.-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Becaplermin (Regranex) is a topical gel indicated to promote the healing of full-thickness, neuropathic, chronic, diabetic ulcers less than or equal to 5 cm<font class=\"super\">2</font>,in association with other good wound care measures.</p><p>A retrospective observational study (unpublished) has raised concerns of a link between becaplermin and malignancies distant from the site of application. The study had several limitations in its design and the evidence is not robust. However, as a precaution, <a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON076452\" target=\"_blank\">a letter has been sent to healthcare professionals in March 2010</a> to inform them of the contraindication of becaplermin in patients with any known malignancy.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Review treatment at the next routine appointment and do not prescribe becaplermin to patients who have a current cancer at any site</li>\r\n\t\t\t\t<li>Ulcers with a suspicious appearance should be biopsied to exclude malignancy<br></li>\r\n\t\t\t</ul></div><p><strong>Further information from the European Medicines Agency:</strong></p><p><a href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/public_health_alerts/2010/02/human_pha_detail_000004.jsp&mid=&murl=menus/medicines/medicines.jsp&jsenabled=true\" target=\"_blank\"><font class=\"trianglelink\">Press release and Questions and answers</font></a></p><p>&nbsp;</p><p><em>Article citation: Drug Safety Update April 2010, vol 3 issue 9: 10.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Becaplermin (Regranex) is a topical gel indicated to promote the healing of full-thickness, neuropathic, chronic, diabetic ulcers less than or equal to 5 cm<font class=\"super\">2</font>,in association with other good wound care measures.</p><p>A retrospective observational study (unpublished) has raised concerns of a link between becaplermin and malignancies distant from the site of application. The study had several limitations in its design and the evidence is not robust. However, as a precaution, <a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON076452\" target=\"_blank\">a letter has been sent to healthcare professionals in March 2010</a> to inform them of the contraindication of becaplermin in patients with any known malignancy.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Review treatment at the next routine appointment and do not prescribe becaplermin to patients who have a current cancer at any site</li>\r\n\t\t\t\t<li>Ulcers with a suspicious appearance should be biopsied to exclude malignancy<br></li>\r\n\t\t\t</ul></div><p><strong>Further information from the European Medicines Agency:</strong></p><p><a href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/public_health_alerts/2010/02/human_pha_detail_000004.jsp&amp;mid=&amp;murl=menus/medicines/medicines.jsp&amp;jsenabled=true\" target=\"_blank\">Press release and Questions and answers<font class=\"trianglelink\">Press release and Questions and answers</font></a></p><p>&#160;</p><p><em>Article citation: Drug Safety Update April 2010, vol 3 issue 9: 10.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2010-04-01", 
  "date_last_modified": "2010-09-15", 
  "_assets": [], 
  "_item_id": 207, 
  "summary": "", 
  "body": "Article date: April 2010\n\nBecaplermin (Regranex) is a topical gel indicated to promote the healing of full-thickness, neuropathic, chronic, diabetic ulcers less than or equal to 5 cm2,in association with other good wound care measures.\n\nA retrospective observational study (unpublished) has raised concerns of a link between becaplermin and malignancies distant from the site of application. The study had several limitations in its design and the evidence is not robust. However, as a precaution, [a letter has been sent to healthcare professionals in March 2010](http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON076452) to inform them of the contraindication of becaplermin in patients with any known malignancy.\n\nAdvice for healthcare professionals:  \n  \n  * Review treatment at the next routine appointment and do not prescribe becaplermin to patients who have a current cancer at any site  \n  * Ulcers with a suspicious appearance should be biopsied to exclude malignancy  \n  \n  \nFurther information from the European Medicines Agency:\n\n[Press release and Questions and answersPress release and Questions and answers](http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/public_health_alerts/2010/02/human_pha_detail_000004.jsp&mid=&murl=menus/medicines/medicines.jsp&jsenabled=true)\n\nÂ \n\nArticle citation: Drug Safety Update April 2010, vol 3 issue 9: 10.\n"
}